Case-control studies on the accuracy of LUS.
| Author, year of publication | Study characteristics | LUS protocol | Results |
|---|---|---|---|
| Tüzün et al., 2025 [30] | Monocentric, case-control studyRA with ILD (n = 35) and RA without ILD (n = 34) | Multifrequency linear probe (6–18 MHz)12 ICSCoalescent LUS score* |
|
| Gutierrez et al., 2022 [29] | Multicenter (2 centers), case-control studyRA patients, regardless of symptoms (n = 74) and healthy controls (n = 74) | Linear probe (5–13 MHz and 4–12 MHz)14 ICSSemiquantitative BL score& |
|
| Mena-Vázquez et al., 2021 [28] | Monocentric, case-control studyRA patients with (n = 35) and without ILD (n = 36) | Convex probe (1–8 MHz)72 ICSTotal number of BL and PI |
|
| Fotoh et al., 2021 [27] | Monocentric, case-control studyRA patients with (n = 75) and without ILD (n = 75) | Linear probe (4–13 MHz)14 ICSTotal number of BLSemiquantitative BL score& |
|
| Moazedi-Fuerst et al., 2014 [26] | Monocentric, case-control studyRA patients without respiratory symptoms (n = 64) and healthy controls (n = 40) | Convex probe (3.5 MHz) and linear probe, 18 ICSLUS positive if BL in > 2 locations, pleural line thickening or fragmentation, subpleural nodules, and negative lung sliding |
|
*: coalescent LUS score: score 0: presence of A lines or BL ≤ 2; score 1: BL ≥ 3; score 2: coalescent BL; score 3: tissue-like pattern; &: semiquantitative BL score: 0 = normal (≤ 5 BL), 1 = mild (≥ 6 and ≤ 15 BL), 2 = moderate (≥ 16 and ≤ 30 BL), and 3 = severe (≥ 30 BL); ACPA: anti-cyclic citrullinated peptide antibodies; BL: B lines; DLCO: carbon monoxide diffusion capacity; HAQ: Health Assessment Questionnaire; HRCT: high-resolution computed tomography; ICS: intercostal spaces; ILD: interstitial lung disease; KL-6: Krebs von den Lungen-6; LUS: lung ultrasound; NPV: negative predictive value; PFT: pulmonary function tests; PI: pleural ultrasound irregularities; RA: rheumatoid arthritis; Se: sensitivity.